Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis

Journal of Immunology

Volumn 163, Issue 2, 1999, Pages 1000-1009

  Quattrocchi, Emilia ^a   Walmsley, Marita ^a,c   Browne, Kylie ^a,d   Williams, Richard O ^a   Marinova Mutafchieva, Lilia ^a   Buurman, Wim ^b   Butler, Debra M ^a   Feldmann, Marc ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; TUMOR NECROSIS FACTOR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DISEASE; GENE TARGETING; GENE THERAPY; HISTOPATHOLOGY; IMMUNOPATHOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0033565794     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Brennan, F. M., D. Chantry, A. Jackson, R. Maini, and M. Feldmann. 1989. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244.
2. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:397.
3. Thorbecke, G. J., R. Shah, C. H. Leu, A. P. Kuruvilla, A. M. Hardison, and M. A. Palladino. 1992. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89:7375.
4. Williams, R. O., M. Feldmann, and R. N. Maini. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89:9784.
5. Elliott, M. J., R. N. Maini, M. Feldmann, A. Long-Fox, P. Charles, P. Katsikis, F. M. Brennan, J. Walker, H. Bijl, J. Ghrayeb, et al. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36:1681.
6. Elliott, M. J., R. N. Maini, M. Feldmann, A. Long-Fox, P. Charles, H. Bijl, and J. N. Woody. 1994. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344:1125.
7. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, H. Bijl, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105.
8. Rankin, E. C., E. H. Choy, D. Kassimos, G. H. Kingsley, A. M. Sopwith, D. A. Isenberg, and G. S. Panayi. 1995. The therapeutic effects of an engineered human anti-tumour necrosis factor α antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34:334.
9. Moreland, L. W., S. W. Baumgartner, M. H. Schiff, E. A. Tindall, R. M. Fleischmann, A. L. Weaver, R. E. Ettlinger, S. Cohen, W. J. Koopman, K. Mohler, M. B. Widmer, and C. M. Blosch. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337:141.
10. Furst, D., M. Weisman, H. Paulus, K. Bulpitt, M. Weinblatt, R. Polisson, P. St. Clair, P. Milnarik, M. Baudin, E. Ludin, T. McAuliffe, M. R. Kahry, W. Lesslauer, and P. van de Auwera. 1996. Neutralization of TNF by lenercept (TNFR 55 TgGt, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of a phase II trial. Arthritis Rheum. 39:S243 (Abstr.).
11. Hasler, F., L. van de Putte, M. Baudin, E. Lodin, L. Durrwell, T. McAuliffe, and P. van de Auwera. 1996. Chronic TNF neutralization (up to 1 year) by lenercept (TNFR 55 IgG1, Ro 45-2081) in patients with rheumatoid arthitis: results from open label extension of a double blind single-dose phase I study. Arthritis Rheum. 39:S243 (Abstr.).
12. Lee, J. C., J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. Green, D. McNulty, M. J. Blumenthal, J. R. Heys, S. W. Landvatter, et al. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739.
13. Semmler, J., H. Wachtel, and S. Endres. 1993. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol. 15:409.
14. Temin, H. M. 1990. Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Hum. Gene Ther. 1:111.
15. Culver, K., K. Cornetta, R. Morgan, S. Morecki, P. Aebersold, A. Kasid, M. Lotze, S. A. Rosenberg, W. F. Anderson, and R. M. Blaese. 1991. Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc. Natl. Acad. Sci. USA 88:3155.
16. Bramson, J. L., F. L. Graham, and J. Gauldie. 1995. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr. Opin. Biotechnol. 6:590.
17. Smith, T. A., M. G. Mehaffey, D. B. Kayda, J. M. Saunders, S. Yei, B. C. Trapnell, A. McClelland, and M. Kaleko. 1993. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet. 5:397.
18. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407.
19. Engelhardt, J. F., X. Ye, B. Doranz, and J. M. Wilson. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91:6196.
20. Kay, M. A., A. X. Holterman, L. Meuse, A. Gown, H. D. Ochs, P. S. Linsley, and C. B. Wilson. 1995. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat. Genet. 11:191.
21. Williams, R. O., M. Feldmann, and R. N. Maini. 1997. Immunotherapy of murine collagen-induced arthritis. In Weir's Handbook of Experimental Immunology, Vol. IV. The Integrated Immune System. L. A. Herzenberg, L. A. Herzenberg, D. M. Weir, and C. Blackwell, eds. Blackwell Science, Oxford, p. 192.1.
22. Marinova-Mutafchieva, L., R. O. Williams, L. J. Mason, C. Mauri, M. Feldmann, and R. N. Maini. 1997. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin. Exp. Immunol. 107: 507.
23. Malfait, A. M., D. M. Butler, D. H. Presky, R. N. Maini, F. M. Brennan, and M. Feldmann. 1998. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. 111:377.
24. Feldmann, M., M. J. Elliott, J. N. Woody, and R. N. Maini. 1997. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv. Immunol. 64:283.
25. Peppel, K., D. Crawford, and B. Beutler. 1991. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174:1483.
26. Kolls, J., K. Peppel, M. Silva, and B. Beutler. 1994. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA 91:215.
27. Graham, F. L., and L. Prevec. 1991. Manipulation of adenovirus vectors. In Gene Transfer and Expression Protocols: Methods in Molecular Biology, Vol. 7. E. J. Murray, ed. The Humana Press, Clifton, NJ, p. 109.
28. Scallon, B. J., H. Trinh, M. Nedelman, F. M. Brennan, M. Feldmann, and J. Ghrayeb. 1995. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine 7:759.
29. Leeuwenberg, J. F. M., T. M. A. A. Jeunhomme, and W. A. Buurman. 1994. Slow release of soluble TNF receptors by monocytes in vitro. J. Immunol. 152:4036.
30. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99.
31. Webb, L. M., M. J. Walmsley, and M. Feldmann. 1996. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26:2320.
32. Bemelmans, M. H., D. Abramowicz, D. J. Gouma, M. Goldman, and W. A. Buurman. 1994. In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice: effects of pentoxifylline, methylprednisolone, anti-TNF, and anti-IFN-γ antibodies. J. Immunol. 153:499.
33. Holmdahl, R., M. Andersson, T. J. Goldschmidt, K. Gustafsson, L. Jansson, and J. A. Mo. 1990. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol. Rev. 118:193.
34. Watson, W. C., and A. S. Townes. 1985. Genetic susceptibility to murine collagen II autoimmune arthritis: proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-MHC loci. J. Exp. Med. 162:1878.
35. Boissier, M. C., A. Carlioz, and C. Fournier. 1988. Experimental autoimmune arthritis in mice. II. Early events in the elicitation of the autoimmune phenomenon induced by homologous type II collagen. Clin. Immunol. Immunopathol. 48:225.
36. Williams, R. O., J. Ghrayeb, M. Feldmann, and R. N. Maini. 1995. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 84:433.
37. Wooley, P. H., J. Dutcher, M. B. Widmer, and S. Gillis. 1993. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 151:6602.
38. Verma, I. M., and N. Somia. 1997. Gene therapy - promises, problems and prospects (news). Nature 389:239.
39. Crystal, R. G. 1995. Transfer of genes to humans: early lessons and obstacles to success. Science 270:404.
40. Kolls, J. K., D. Lei, S. Nelson, W. R. Summer, S. Greenberg, and B. Beutler. 1995. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J. Infect. Dis. 171: 570.
41. Kolls, J. K., D. Lei, G. Odom, S. Nelson, W. R. Summer, M. A. Gerber, and J. E. Shellito. 1996. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum. Gene Ther. 7:489.
42. Mori, L., S. Iselin, G. De Libero, and W. Lesslauer. 1996. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J. Immunol. 157:3178.
43. Piguet, P. F., G. E. Grau, C. Vesin, H. Loetscher, R. Gentz, and W. Lesslauer. 1992. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510.
44. Bemelmans, M. H., L. J. van Tits, and W. A. Buurman. 1996. Tumor necrosis factor: function, release and clearance. Crit. Rev. Immunol. 16:1.
45. Maini, R. N., F. C. Breedveld, J. R. Kalden, J. S. Smolen, D. Davis, J. D. Macfarlane, C. Antoni, B. Leeb, M. J. Elliott, J. N. Woody, T. F. Schaible, and M. Feldmann. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41:1552.
46. Marino, M. W., A. Dunn, D. Grail, M. Inglese, Y. Noguchi, E. Richards, A. Jungbluth, H. Wada, M. Moore, B. Williamson, S. Basu, and L. J. Old. 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 94:8093.
47. Cope, A. P., M. Londei, N. R. Chu, S. B. Cohen, M. J. Elliott, F. M. Brennan, R. N. Maini, and M. Feldmann. 1994. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J. Clin. Invest. 94:749.
48. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
49. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
50. Engelmann, H., H. Holtmann, C. Brakebusch, Y. S. Avni, I. Sarov, Y. Nophar, E. Hadas, O. Leitner, and D. Wallach. 1990. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J. Biol. Chem. 265:14497.
51. Evans, T. J., D. Moyes, A. Carpenter, R. Martin, H. Loetscher, W. Lesslauer, and J. Cohen. 1994. Protective effect of 55-but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J. Exp. Med. 180:2173.
52. Christen, U., R. Thuerkauf, and W. Lesslauer. 1998. Immunogenicity of a human TNFR55-IgG1 fusion protein (lenercept) in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients. J. Interferon Cytokine Res. 18:A-121 (Abstr.).
53. Klein, B., and H. Brailly. 1995. Cytokine-binding proteins: stimulating antagonists. Immunol. Today 16:216.
54. Aderka, D., H. Engelmann, Y. Maor, C. Brakebusch, and D. Wallach. 1992. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175:323.
55. Mohler, K. M., D. S. Torrance, C. A. Smith, R. G. Goodwin, K. E. Stremler, V. P. Fung, H. Madani, and M. B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. 151:1548.
56. Fisher, C. J. J., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334:1697.
57. Arnason, B. G. W. 1998. Blocking cytokines: rTNF-α inhibition in MS. In International Workshop in Th1/Th2: T-Cell Differentiation in MS and Autoimmunity, National Multiple Sclerosis Society, Nashville, TN, p. 95.